[go: up one dir, main page]

AU2003284899A1 - Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake - Google Patents

Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake

Info

Publication number
AU2003284899A1
AU2003284899A1 AU2003284899A AU2003284899A AU2003284899A1 AU 2003284899 A1 AU2003284899 A1 AU 2003284899A1 AU 2003284899 A AU2003284899 A AU 2003284899A AU 2003284899 A AU2003284899 A AU 2003284899A AU 2003284899 A1 AU2003284899 A1 AU 2003284899A1
Authority
AU
Australia
Prior art keywords
blockade
prefrontal
adjunctive
reuptake
schizophrenia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003284899A
Other languages
English (en)
Other versions
AU2003284899A8 (en
Inventor
Stacy A. Castner
Graham V. Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MIICRO Inc
Original Assignee
MIICRO Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MIICRO Inc filed Critical MIICRO Inc
Publication of AU2003284899A8 publication Critical patent/AU2003284899A8/xx
Publication of AU2003284899A1 publication Critical patent/AU2003284899A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2003284899A 2002-10-29 2003-10-24 Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake Abandoned AU2003284899A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42198002P 2002-10-29 2002-10-29
US60/421,980 2002-10-29
PCT/US2003/033730 WO2004039322A2 (fr) 2002-10-29 2003-10-24 Nouvelle polytherapie pour la schizophrenie, fondee sur une cognition amelioree : blocage de 5-ht-2a/d2 avec blocage auxiliaire du recaptage da prefrontal

Publications (2)

Publication Number Publication Date
AU2003284899A8 AU2003284899A8 (en) 2004-05-25
AU2003284899A1 true AU2003284899A1 (en) 2004-05-25

Family

ID=32230298

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003284899A Abandoned AU2003284899A1 (en) 2002-10-29 2003-10-24 Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake

Country Status (2)

Country Link
AU (1) AU2003284899A1 (fr)
WO (1) WO2004039322A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2397981C (fr) 2000-03-06 2010-12-21 Acadia Pharmaceuticals, Inc. Composes azacycliques utilises dans le traitement de maladies liees a la serotonine
ATE466014T1 (de) 2001-12-28 2010-05-15 Acadia Pharm Inc Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
MXPA04012893A (es) 2002-06-24 2005-03-31 Acadia Pharm Inc Derivados de piperidina n-substituidos como agentes receptores de serotonina.
US7601740B2 (en) 2003-01-16 2009-10-13 Acadia Pharmaceuticals, Inc. Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
DK1794126T3 (da) 2004-09-27 2013-06-24 Acadia Pharm Inc Krystallinsk form af N-(-4-fluorbenzyl)-N-(1-methylpiperidn-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamid-hemitartrat
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
ES2423485T3 (es) 2007-03-19 2013-09-20 Acadia Pharmaceuticals Inc. Asociaciones de agonistas y antagonistas inversos 5-HT2A con antipsicóticos
JP2011519873A (ja) * 2008-05-07 2011-07-14 ハー・ルンドベック・アクチエゼルスカベット 認知欠損を治療する方法
ES2890492T3 (es) 2015-07-20 2022-01-20 Acadia Pharm Inc Métodos para preparar N-(4-fluorobencil)-N-(1-metilpiperidin-4-il)-N'-(4-(2-metilpropiloxi)fenilmetil)carbamida y su sal de tartrato y forma polimórfica C
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (fr) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Association de pimavansérine et de modulateurs du cytochrome p450
WO2018118626A1 (fr) 2016-12-20 2018-06-28 Acadia Pharmaceuticals Inc. Pimavansérine seule ou en association pour une utilisation dans le traitement de la psychose liée à la maladie d'alzheimer
CN110087641B (zh) 2016-12-20 2024-03-12 罗曼治疗系统股份公司 含有阿塞那平和聚硅氧烷或聚异丁烯的透皮治疗系统
KR102506333B1 (ko) 2016-12-20 2023-03-06 에르테에스 로만 테라피-시스테메 아게 아세나핀을 함유하는 경피흡수 치료 시스템
EP3615028A1 (fr) 2017-04-28 2020-03-04 Acadia Pharmaceuticals Inc. Pimavansérine pour le traitement d'un trouble de contrôle des impulsions
EP3644973B1 (fr) 2017-06-26 2021-03-24 LTS LOHMANN Therapie-Systeme AG Système thérapeutique transdermique contenant de l'asénapine et polymère hybride acrylique silicone
EP3675827A1 (fr) 2017-08-30 2020-07-08 Acadia Pharmaceuticals Inc. Formulations de pimavansérine
CN112704672A (zh) 2018-06-20 2021-04-27 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
CN112533593A (zh) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294520B1 (en) * 1989-03-27 2001-09-25 Albert T. Naito Material for passage through the blood-brain barrier
US6599532B2 (en) * 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent

Also Published As

Publication number Publication date
AU2003284899A8 (en) 2004-05-25
WO2004039322A2 (fr) 2004-05-13
WO2004039322A3 (fr) 2004-10-07

Similar Documents

Publication Publication Date Title
AU2003284899A1 (en) Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake
AU2003220553A1 (en) Combination therapy for the treatment of conditions with pathogenic inflammatory components
AU2002255190A1 (en) Composition for enhanced absorption of nsaids
AU2003248882A1 (en) Affinity small molecules for the epo receptor
AU2003293363A1 (en) Process for the synthesis of bisphenol
AU2002365869A1 (en) Purification of polyolefin feedstocks using multiple adsorbents
AU2002244568A1 (en) Individualization of therapy with antipsychotics
IL160143A0 (en) Novel imidazopyridine compounds with therapeutic effect
AU2002358105A1 (en) Anti-microbial, anti-inflammatory glass-ceramic, which absorbs uv radiation
AU2002302223A1 (en) Individualization of therapy with analgesics
AU2002335667A1 (en) Modified reoviral therapy
AU2002308723A1 (en) Dual fiber collimator
AU2002254947A1 (en) Kappa opiate agonists for the treatment of bladder diseases
AU2002339810A1 (en) Azabicyclic compounds for the treatment of fibromyalgia syndrome
AU2003220338A1 (en) Photosensitizers for photodynamic therapy of microbial infections
AU2003225258A1 (en) Fiber treatment composition
AU2001260616A1 (en) Compounds generating amine by irradiation with light, photo-setting compositions and photoreactive adhesive compositions
AU2003224495A1 (en) Process for the preparation of enantiomerically enriched compounds
AU2002339699A1 (en) Use of obg3 for promoting central nervous system remyelination
AU2002342488A1 (en) Individualization of therapy with anesthetics
AU2002249042A1 (en) Individualization of therapy with hyperlipidemia agents
AUPR713201A0 (en) Novel therapeutic molecules and uses therefor
AU2002312949A1 (en) Process for the preparation of bisphenols with zeolites
AU2002347791A1 (en) Ultra-violet light curable hot melt composition
AU2002333079A1 (en) Individualization of therapy with anxiolitics

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase